ALNY vs. HLN: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALNY and HLN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ALNY’s market capitalization stands at 40.06 billion USD, while HLN’s is 47.83 billion USD, indicating their market valuations are broadly comparable.
With betas of 0.21 for ALNY and 0.24 for HLN, both stocks show similar sensitivity to overall market movements.
HLN is an American Depositary Receipt (ADR), allowing U.S. investors direct exposure to its non-U.S. operations. ALNY, on the other hand, is a domestic entity.
| Symbol | ALNY | HLN |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Haleon plc |
| Country | US | GB |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. | Mr. Brian James McNamara |
| Price | 307.255 USD | 10.565 USD |
| Market Cap | 40.06 billion USD | 47.83 billion USD |
| Beta | 0.21 | 0.24 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 1, 2004 | July 25, 2022 |
| ADR | No | Yes |
Historical Performance
This chart compares the performance of ALNY and HLN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALNY
-509.33%
Biotechnology Industry
- Max
- 160.48%
- Q3
- -7.20%
- Median
- -56.04%
- Q1
- -120.86%
- Min
- -282.47%
ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
HLN
8.73%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 93.04%
- Q3
- 8.73%
- Median
- -11.44%
- Q1
- -55.69%
- Min
- -140.76%
HLN’s Return on Equity of 8.73% is on par with the norm for the Drug Manufacturers - Specialty & Generic industry, indicating its profitability relative to shareholder equity is typical for the sector.
Return on Invested Capital
ALNY
-2.79%
Biotechnology Industry
- Max
- 90.96%
- Q3
- -23.73%
- Median
- -52.59%
- Q1
- -101.56%
- Min
- -216.70%
ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
HLN
5.68%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 43.09%
- Q3
- 5.22%
- Median
- -8.71%
- Q1
- -43.46%
- Min
- -115.83%
HLN’s Return on Invested Capital of 5.68% is in the upper quartile for the Drug Manufacturers - Specialty & Generic industry, signifying a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ALNY
-11.49%
Biotechnology Industry
- Max
- 3,408.18%
- Q3
- -60.78%
- Median
- -412.44%
- Q1
- -3,032.88%
- Min
- -7,417.79%
ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceed revenues.
HLN
12.84%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 86.91%
- Q3
- 1.49%
- Median
- -16.74%
- Q1
- -101.02%
- Min
- -169.71%
HLN’s Net Profit Margin of 12.84% is in the upper quartile for the Drug Manufacturers - Specialty & Generic industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ALNY
-4.91%
Biotechnology Industry
- Max
- 3,462.86%
- Q3
- -79.64%
- Median
- -472.72%
- Q1
- -3,191.70%
- Min
- -7,857.88%
ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
HLN
19.64%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 98.79%
- Q3
- 7.62%
- Median
- -13.24%
- Q1
- -67.70%
- Min
- -143.53%
HLN’s Operating Profit Margin of 19.64% is in the upper quartile for the Drug Manufacturers - Specialty & Generic industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ALNY | HLN |
|---|---|---|
| Return on Equity (TTM) | -509.33% | 8.73% |
| Return on Assets (TTM) | -6.40% | 4.20% |
| Return on Invested Capital (TTM) | -2.79% | 5.68% |
| Net Profit Margin (TTM) | -11.49% | 12.84% |
| Operating Profit Margin (TTM) | -4.91% | 19.64% |
| Gross Profit Margin (TTM) | 86.01% | 61.52% |
Financial Strength
Current Ratio
ALNY
3.04
Biotechnology Industry
- Max
- 19.64
- Q3
- 9.18
- Median
- 4.46
- Q1
- 2.01
- Min
- 0.00
ALNY’s Current Ratio of 3.04 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
HLN
0.98
Drug Manufacturers - Specialty & Generic Industry
- Max
- 6.36
- Q3
- 3.34
- Median
- 2.34
- Q1
- 1.07
- Min
- 0.01
HLN’s Current Ratio of 0.98 falls into the lower quartile for the Drug Manufacturers - Specialty & Generic industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
ALNY
11.28
Biotechnology Industry
- Max
- 0.86
- Q3
- 0.36
- Median
- 0.09
- Q1
- 0.02
- Min
- 0.00
ALNY’s Debt-to-Equity Ratio of 11.28 is exceptionally high, falling well outside the typical range for the Biotechnology industry. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates the company’s financial risk.
HLN
0.62
Drug Manufacturers - Specialty & Generic Industry
- Max
- 2.54
- Q3
- 1.11
- Median
- 0.34
- Q1
- 0.08
- Min
- 0.00
HLN’s Debt-to-Equity Ratio of 0.62 is typical for the Drug Manufacturers - Specialty & Generic industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
ALNY
-0.79
Biotechnology Industry
- Max
- 143.86
- Q3
- -5.85
- Median
- -29.74
- Q1
- -170.62
- Min
- -397.83
ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its operating earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
HLN
5.60
Drug Manufacturers - Specialty & Generic Industry
- Max
- 32.89
- Q3
- 1.21
- Median
- -2.35
- Q1
- -21.57
- Min
- -53.19
HLN’s Interest Coverage Ratio of 5.60 is in the upper quartile for the Drug Manufacturers - Specialty & Generic industry, signifying a strong and healthy capacity to meet its interest payments out of operating profits.
Financial Strength at a Glance
| Symbol | ALNY | HLN |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 0.98 |
| Quick Ratio (TTM) | 2.98 | 0.78 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 0.62 |
| Debt-to-Asset Ratio (TTM) | 0.31 | 0.29 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.85 | 3.41 |
| Interest Coverage Ratio (TTM) | -0.79 | 5.60 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALNY and HLN. These metrics are based on the companies’ annual financial reports.
Revenue Growth (YoY)
EPS Growth (YoY)
Free Cash Flow Growth (YoY)
Dividend
Dividend Yield
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting all earnings back into the business, though it may be less typical in mature, income-oriented sectors.
HLN
1.71%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 6.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HLN’s Dividend Yield of 1.71% is in the upper quartile for the Drug Manufacturers - Specialty & Generic industry, offering a more attractive income stream than most of its peers and signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This typically means all profits are being reinvested for growth.
HLN
0.00%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 87.92%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HLN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This typically means all profits are being reinvested for growth.
Dividend at a Glance
| Symbol | ALNY | HLN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.71% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ALNY
-147.73
Biotechnology Industry
- Max
- 94.36
- Q3
- 51.53
- Median
- 15.96
- Q1
- 6.14
- Min
- 0.00
ALNY has a negative P/E Ratio of -147.73, indicating it has a net loss. A negative P/E is not a reliable indicator for valuation comparisons.
HLN
24.37
Drug Manufacturers - Specialty & Generic Industry
- Max
- 64.11
- Q3
- 31.27
- Median
- 21.37
- Q1
- 8.88
- Min
- 0.00
HLN’s P/E Ratio of 24.37 is comparable to the norm for the Drug Manufacturers - Specialty & Generic industry, suggesting its valuation is neither at a significant premium nor a discount to its peers.
Forward P/E to Growth Ratio
ALNY
-40.07
Biotechnology Industry
- Max
- 1.10
- Q3
- 0.45
- Median
- 0.09
- Q1
- 0.02
- Min
- 0.00
ALNY has a negative Forward PEG Ratio of -40.07. This typically results from either negative earnings (a current loss) or forecasts of declining future earnings, making the ratio not meaningful for valuation purposes.
HLN
-0.24
Drug Manufacturers - Specialty & Generic Industry
- Max
- 3.31
- Q3
- 1.41
- Median
- 0.14
- Q1
- 0.02
- Min
- 0.00
HLN has a negative Forward PEG Ratio of -0.24. This typically results from either negative earnings (a current loss) or forecasts of declining future earnings, making the ratio not meaningful for valuation purposes.
Price-to-Book Ratio
ALNY
345.16
Biotechnology Industry
- Max
- 10.92
- Q3
- 4.88
- Median
- 1.80
- Q1
- 0.65
- Min
- 0.00
The P/B Ratio isn’t typically a primary valuation metric for companies in the Biotechnology industry.
HLN
2.17
Drug Manufacturers - Specialty & Generic Industry
- Max
- 7.77
- Q3
- 3.69
- Median
- 1.65
- Q1
- 0.57
- Min
- 0.00
The P/B Ratio isn’t typically a primary valuation metric for companies in the Drug Manufacturers - Specialty & Generic industry.
Price-to-Sales Ratio
ALNY
17.06
Biotechnology Industry
- Max
- 141.58
- Q3
- 60.06
- Median
- 10.51
- Q1
- 2.88
- Min
- 0.00
ALNY’s P/S Ratio of 17.06 is valued in line with its peers in the Biotechnology industry, suggesting the market’s valuation of its sales is typical for the sector.
HLN
3.08
Drug Manufacturers - Specialty & Generic Industry
- Max
- 9.71
- Q3
- 4.95
- Median
- 1.51
- Q1
- 0.50
- Min
- 0.00
HLN’s P/S Ratio of 3.08 is valued in line with its peers in the Drug Manufacturers - Specialty & Generic industry, suggesting the market’s valuation of its sales is typical for the sector.
Valuation at a Glance
| Symbol | ALNY | HLN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -147.73 | 24.37 |
| Forward PEG Ratio (TTM) | -40.07 | -0.24 |
| Price-to-Sales Ratio (P/S, TTM) | 17.06 | 3.08 |
| Price-to-Book Ratio (P/B, TTM) | 345.16 | 2.17 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -531.44 | -- |
| EV-to-EBITDA (TTM) | -264.26 | 18.34 |
| EV-to-Sales (TTM) | 17.18 | 3.79 |